Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 238
- Registration Number
- NCT06733038
- Locations
- 🇮🇹
Istituto Oncologico Veneto Irccs, Padova, PD, Italy
🇮🇹Nuovo Ospedale di Prato S. Stefano, Prato, PO, Italy
🇮🇹U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT06628310
- Locations
- 🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸Hattiesburg Clinic /ID# 268572, Hattiesburg, Mississippi, United States
🇺🇸Millennium Research & Clinical Development /ID# 268540, Houston, Texas, United States
Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06625320
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- 🇨🇳
Hsin-Chu Hospital, Hsin-chu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT06586515
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸City of Hope Medical Group, South Pasadena, California, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 54
- Registration Number
- NCT06509906
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Health One, Denver, Colorado, United States
🇦🇺St George Private Hospital, Kogarah, Australia
🇦🇺Peter MacCallum Cancer Centre - Use the one with Account 2 VCCC, Parkville, Australia
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
- Conditions
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT06490913
The Sagittarius Trial
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 700
- Registration Number
- NCT06490536
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto di Candiolo, Candiolo, Torino, Italy
🇮🇹Azienda Sanitaria Locale di Biella, Biella, Italy
Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06469944
- Locations
- 🇺🇸
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927), Tucson, Arizona, United States
🇧🇷Liga Norte Riograndense Contra o Câncer ( Site 6303), Natal, Rio Grande Do Norte, Brazil
🇩🇪Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 6807), Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.